The prognostic time dependence of intra-tumoural IFNγ mRNA and protein in patients with breast cancer followed for 14 years after surgery and radiotherapy, without subsequent systemic therapy

There is increasing evidence for the importance of immunity in breast cancer. IFNγ is expected to have a prognostic value based on its major role in innate and specific cell-mediated immunity. In this retrospective study, based on the 14-year follow-up of 73 patients with breast cancer after surgery and radiotherapy but no subsequent systemic therapy, we investigated the prognostic time dependence of intra-tumoural IFNγ mRNA and protein levels. Over the entire 14 years of follow-up, neither IFNγ mRNA nor protein was significantly associated with metastasis outcome by AUC and Cox regression criteria. However, evaluation of the shorter periods has revealed a prognostic significance in the late follow-up period of 7-14 years for IFNγ mRNA and protein with the maximal respective AUCs of 0.72 and 0.73 and hazard ratios of 6.1 and 5.2, respectively. Interestingly, the opposite prognostic association was discovered for IFNγ mRNA and protein in the first 7 years of follow-up, possibly due to the negative correlation of IFNγ protein and mRNA. Moreover, the prognostic association of IFNγ mRNA has shifted from marking the favourable outcome in the first 7 years to poor outcome thereafter. This study contributes to clarification of the previously inconsistent prognostic performance of IFNγ by providing the first prognostic evaluation with long follow-up, time-dependence assessment and absence of any chemotherapy influence.

[1]  H. T. Park,et al.  Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response , 2017, Nature Communications.

[2]  Nan Zhang,et al.  PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer , 2017, International Journal of Clinical Oncology.

[3]  R. Shamir,et al.  Reduced changes in protein compared to mRNA levels across non-proliferating tissues , 2017, BMC Genomics.

[4]  L. Owens,et al.  Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation. , 2016, Journal of biotechnology.

[5]  Zeming Liu,et al.  Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis , 2016, PloS one.

[6]  A. Butte,et al.  Cross-tissue Analysis of Gene and Protein Expression in Normal and Cancer Tissues , 2016, Scientific Reports.

[7]  P. Hertzog,et al.  Antitumour actions of interferons: implications for cancer therapy , 2016, Nature Reviews Cancer.

[8]  F. Annunziato,et al.  The 3 major types of innate and adaptive cell-mediated effector immunity. , 2015, The Journal of allergy and clinical immunology.

[9]  G. Merlino,et al.  The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.

[10]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[11]  Chia-Der Lin,et al.  Increased programmed death‐ligand‐1 expression in human gastric epithelial cells in Helicobacter pylori infection , 2010, Clinical and experimental immunology.

[12]  Gaëtan MacGrogan,et al.  Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer , 2010, BMC medical research methodology.

[13]  Albert Koong,et al.  Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.

[14]  David E Levy,et al.  IFNgamma signaling-does it mean JAK-STAT? , 2008, Cytokine & growth factor reviews.

[15]  D. Laune,et al.  Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.

[16]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[17]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[18]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[19]  K. Omura,et al.  The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. , 2004, Immunology letters.

[20]  A. López-Rivas,et al.  Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism* , 2001, The Journal of Biological Chemistry.

[21]  E. Tartour,et al.  Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. , 1998, Journal of the National Cancer Institute.

[22]  G. Shaw,et al.  Translational blockade imposed by cytokine-derived UA-rich sequences. , 1989, Science.

[23]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[24]  Jianguo Feng,et al.  Clinicopathological and prognostic significance of serum cytokine levels in breast cancer. , 2014, Clinical Laboratory.

[25]  H. Fiegl,et al.  Interferon-gamma expression is an independent prognostic factor in ovarian cancer. , 2004, American journal of obstetrics and gynecology.

[26]  Lloyd J. Old,et al.  and shape tumour immunogenicity , 2001 .